ArticleClinical pharmacokinetics2010

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Gezim Lahu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.